Health Care · Services-General Medical & Surgical Hospitals, NEC · NYSE · CIK 860730 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $408.18Day −2.39%Mkt cap $90.6BP/E (FY) 14.4×1Y +19.3%Off 52W high −26.7%Vol (1Y) 30.5%
Daily closing price, split-adjusted to the current basis; 3y shown of 3,866 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Fair value (model)$629.44 |
| Implied upside+54.2% |
| Valuation confidenceLOW |
| Price impliesUNDEMANDING · 3.3% growth |
| Short interest2.6% of sh out |
| Days to cover3.1d |
| 13F net flow (QoQ)−1.89% |
| Top-10 13F concentration47.7% |
| Next report (est.)2026-10-23 |
Fair value, confidence and the reverse-DCF grade are the MATERIALIZED daily snapshot (the same columns the screener serves), not a live model run. Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| P/E (FY)14.4× |
| Sales (TTM)$76.39B |
| YTD−12.3% |
| 1Y+19.3% |
| 3Y+53.2% |
| 5Y+71.7% |
| 10Y+472.3% |
| Since incept. (ann.)+20.6% |
Total return through 2026-07-29 · series begins 2011-03-10. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)30.5% |
| Ann. volatility (3Y)27.6% |
| Sharpe (1Y)0.78 |
| Sharpe (3Y)0.66 |
| Max drawdown (1Y)−33.6% |
| Max drawdown (3Y)−33.6% |
| Beta (3Y vs SPY)0.44 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| BlackRock, Inc. | 13.4M | $6.3B | 6.02% | +6.2% |
| VANGUARD CAPITAL MANAGEMENT LLC | 10.2M | $4.8B | 4.59% | new |
| Sanders Capital, LLC | 9.0M | $4.2B | 4.04% | −14.4% |
| STATE STREET CORP | 7.5M | $3.6B | 3.40% | −0.4% |
| FMR LLC | 4.4M | $2.1B | 1.98% | +14.8% |
| WELLINGTON MANAGEMENT GROUP LLP | 3.9M | $1.8B | 1.76% | +14.1% |
| GEODE CAPITAL MANAGEMENT, LLC | 3.7M | $1.7B | 1.66% | +0.8% |
| First Eagle Investment Management, LLC | 3.3M | $1.5B | 1.47% | −10.7% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-04-24 | $7.15 | +10.9% | $19.11B | +4.3% |
| 2025-12-31 | 2026-01-27 | — | — | $19.51B | +6.7% |
| 2025-09-30 | 2025-10-24 | $6.96 | +42.6% | $19.16B | +9.6% |
| 2025-06-30 | 2025-07-25 | $6.83 | +23.5% | $18.61B | +6.4% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-10-23 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
Corporate And Other 100%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
| Earnings (TTM)$6.79B |
| Net margin9.0% |
| EPS growth 3Y13.9% |
| Sales growth 3Y7.9% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
